Jonathan D. Schoenfeld, MD, MPH, on Oral Cavity Cancer: Neoadjuvant Nivolumab With or Without Ipilimumab

March 03, 2020 By The ASCO Post Staff

Jonathan D. Schoenfeld, MD, MPH, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses phase II study results with the PD-1 inhibitor nivolumab or the combination of PD-1/CTLA-4 inhibition with nivolumab/ipilimumab in patients with newly diagnosed untreated oral cavity cancer (Abstract 1).

Related Content